GE HealthCare Begins Phase 2/3 Trial for Manganese-Based MRI Contrast Agent
The investigational agent, mangaciclanol, is being developed as an alternative to gadolinium-based contrast agents and has received FDA Fast Track designation.
The investigational agent, mangaciclanol, is being developed as an alternative to gadolinium-based contrast agents and has received FDA Fast Track designation.
New analysis shows that avoidable medical scans could generate as much CO₂ as powering a town of over 70,000 people for a year.
Using multiparametric MRI as the first diagnostic tool for muscle-invasive bladder cancer significantly reduces treatment time by 45 days, modernizes care, and lowers the need for invasive surgical procedures.
A study found that higher Medicaid reimbursement rates are linked to increased medical imaging utilization, highlighting disparities in access to care and the need to address reimbursement gaps to improve equity for underserved populations.
Read MoreX-ray–induced acoustic CT enables 3D imaging from a single X-ray projection, reducing radiation exposure, improving efficiency, and offering a compact alternative to traditional CT systems.
Read MoreA deep learning model using a single inhalation lung CT scan combined with clinical data can accurately diagnose and stage COPD, reducing the need for dual-phase imaging and improving accessibility, according to a study in Radiology: Cardiothoracic Imaging.
Read MoreA study from Washington University School of Medicine highlights an AI-based mammogram analysis method that detects breast cancer risk 2.3 times more accurately than traditional methods, offering equitable and improved early detection across diverse populations.
Read MoreThe incidence of late-stage, metastatic breast cancer at diagnosis significantly increased among U.S. women of all ages and ethnicities from 2004 to 2021, with disparities linked to screening access, healthcare inequities, and demographic factors.
Read More